Physician profile
Anthony P Macarthy
NPI 1629300470
$4,127.07
in general payments reported to CMS, 2019-2025
26 companies · $853 in 2025
The $853 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.74 · 2020: $443 · 2021: $499 · 2022: $838 · 2023: $815 · 2024: $607 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,275.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $930.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $444.05 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $351.20 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Gilead Sciences, INC. | $291.29 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $283.22 | 2021-2024 | |
| Lundbeck LLC | $261.61 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.20 | 2020-2025 | Caplyta |
| Pfizer INC. | $216.57 | 2023-2025 | |
| Allergan, INC. | $177.45 | 2019-2020 | |
| Astellas Pharma US INC | $145.70 | 2020-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $100.60 | 2022-2025 | Zoryve, Seglentis |
| Amgen INC. | $100.46 | 2024-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $98.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $91.54 | 2021 | |
| Exact Sciences Corporation | $76.30 | 2023-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $58.42 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.07 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.13 | 2022 | |
| Phadia US INC. | $35.89 | 2024 | Immunocap |
| Glaxosmithkline, LLC. | $35.80 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $22.99 | 2024 | Rybelsus |
| Hologic Sales and Service, LLC | $22.60 | 2025 | Aptima |
| Abbott Laboratories | $19.29 | 2023 | Proclaim |
| Alkermes, INC. | $18.01 | 2024 | Aristada, Lybalvi |
| Janssen Scientific Affairs, LLC | $14.05 | 2025 | Invega Sustenna |
| Eisai INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Macarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.